JP2013512278A5 - - Google Patents

Download PDF

Info

Publication number
JP2013512278A5
JP2013512278A5 JP2012542150A JP2012542150A JP2013512278A5 JP 2013512278 A5 JP2013512278 A5 JP 2013512278A5 JP 2012542150 A JP2012542150 A JP 2012542150A JP 2012542150 A JP2012542150 A JP 2012542150A JP 2013512278 A5 JP2013512278 A5 JP 2013512278A5
Authority
JP
Japan
Prior art keywords
seq
antibody
pharmaceutical composition
tumor
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012542150A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013512278A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/058511 external-priority patent/WO2011068840A1/en
Publication of JP2013512278A publication Critical patent/JP2013512278A/ja
Publication of JP2013512278A5 publication Critical patent/JP2013512278A5/ja
Pending legal-status Critical Current

Links

JP2012542150A 2009-12-01 2010-12-01 Ｋ−ｒａｓ変異を含んだ癌を処置するための方法 Pending JP2013512278A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26555909P 2009-12-01 2009-12-01
US61/265,559 2009-12-01
PCT/US2010/058511 WO2011068840A1 (en) 2009-12-01 2010-12-01 Methods for treating cancers comprising k-ras mutations

Publications (2)

Publication Number Publication Date
JP2013512278A JP2013512278A (ja) 2013-04-11
JP2013512278A5 true JP2013512278A5 (enExample) 2014-01-23

Family

ID=44115253

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012542150A Pending JP2013512278A (ja) 2009-12-01 2010-12-01 Ｋ−ｒａｓ変異を含んだ癌を処置するための方法

Country Status (5)

Country Link
US (2) US20110165162A1 (enExample)
EP (1) EP2506875A4 (enExample)
JP (1) JP2013512278A (enExample)
CA (1) CA2782299A1 (enExample)
WO (1) WO2011068840A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2664738C (en) 2006-09-29 2017-03-07 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US8883145B2 (en) 2009-10-16 2014-11-11 Oncomed Pharmaceuticals, Inc. Methods of treatment with DLL4 antagonists and an anti-hypertensive agent
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
JP6170496B2 (ja) 2011-09-23 2017-07-26 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｖｅｇｆ／ｄｌｌ４結合剤およびその使用
WO2013119923A1 (en) 2012-02-09 2013-08-15 The Regents Of The University Of Michigan Different states of cancer stem cells
JP6371294B2 (ja) 2012-10-31 2018-08-08 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｄｌｌ４アンタゴニストによる処置の方法およびモニタリング
JP2015030720A (ja) * 2013-08-07 2015-02-16 一丸ファルコス株式会社 キネシン抑制剤
WO2016070051A2 (en) 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
EP3353204B1 (en) 2015-09-23 2023-10-18 Mereo BioPharma 5, Inc. Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer
WO2018112420A1 (en) * 2016-12-15 2018-06-21 The Regents Of The University Of California Compositions and methods for treating cancer
EP3810182A4 (en) 2018-06-19 2022-08-24 BioNTech US Inc. Neoantigens and uses thereof
CA3119458A1 (en) 2018-11-15 2020-05-22 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with vegf/dll4 binding agent
CN112394168B (zh) * 2019-08-15 2023-02-14 中山大学附属第六医院 IgA2检测试剂在制备KRAS突变型结直肠癌诊断剂方面的应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050112121A1 (en) * 1992-04-30 2005-05-26 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
ATE442373T1 (de) * 1995-06-28 2009-09-15 Imp Cancer Res Tech Nukleotid- und proteinsequenzen von delta-genen von vertebraten und darauf basierende methoden
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6121045A (en) * 1997-04-04 2000-09-19 Millennium Biotherapeutics, Inc. Human Delta3 nucleic acid molecules
US20060122373A1 (en) * 1997-04-04 2006-06-08 Millennium Pharmaceuticals, Inc. Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof
US20030180784A1 (en) * 1997-04-04 2003-09-25 Millennium Pharmaceuticals, Inc. Novel human Delta3 compositions and therapeutic and diagnostic uses therefor
EP1004669B1 (en) * 1997-05-14 2007-04-18 Asahi Kasei Kabushiki Kaisha Novel differentiation inhibitor
US6004528A (en) * 1997-09-18 1999-12-21 Bergstein; Ivan Methods of cancer diagnosis and therapy targeted against the cancer stemline
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US20050089518A1 (en) * 2001-12-07 2005-04-28 Clarke Michael F. Prospective identification and characterization of breast cancer stem cells
US6689744B2 (en) * 2000-09-22 2004-02-10 Genentech, Inc. Notch receptor agonists and uses
EP1410018A1 (en) * 2001-07-25 2004-04-21 Lorantis Limited Method for detecting modultators of notch signalling
AU2002339157A1 (en) * 2001-11-14 2003-05-26 Lorantis Limited Inhibitors of the notch signalling pathway for use in the treatment of cancer
US20050137130A1 (en) * 2001-11-14 2005-06-23 Bodmer Mark W. Medical treatment
GB0218879D0 (en) * 2002-08-14 2002-09-25 Lorantis Ltd Medical treatment
WO2004024764A1 (en) * 2002-09-10 2004-03-25 Lorantis Limited Pharmaceutical composition and medical treatments comprising notch ligand proteins
US20060134121A1 (en) * 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
US8048418B2 (en) * 2004-10-29 2011-11-01 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
US7906116B2 (en) * 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
AU2006287228B2 (en) * 2005-09-01 2012-12-13 Alora Biopharma, Inc. Methods for using and identifying modulators of Delta-like 4
JP5489465B2 (ja) * 2005-12-16 2014-05-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｄｌｌ４アンタゴニストによって腫瘍増殖を阻害する治療方法
KR20090016762A (ko) * 2006-06-06 2009-02-17 제넨테크, 인크. 혈관 발달을 조정하기 위한 조성물 및 방법
CA2654000A1 (en) * 2006-06-06 2008-05-22 Genentech, Inc. Anti-dll4 antibodies and methods using same
CA2664738C (en) * 2006-09-29 2017-03-07 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
NO347649B1 (no) * 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
WO2009100349A1 (en) * 2008-02-09 2009-08-13 The Trustees Of Columbia University In The City Of New York Analogues of (-)-picropodophyllin, synthesis and uses thereof

Similar Documents

Publication Publication Date Title
JP2013512278A5 (enExample)
JP6767362B2 (ja) リンパ球における阻害経路の中和
CN108884163B (zh) 对淋巴细胞中抑制途径的中和
JP2014524746A5 (enExample)
KR20170068458A (ko) 항-ｎｋｇ2ａ 항체를 사용한 치료 요법
JP2015506912A5 (enExample)
HRP20221226T1 (hr) Protutijela protiv pd-1 i postupci njihove upotrebe
JP2017149720A5 (enExample)
WO2014012007A4 (en) Rspo3 binding agents and uses thereof
JP2018503365A5 (enExample)
JP2015529641A5 (enExample)
JP7459058B2 (ja) Ｃｄ１３７／ｈｅｒ２二重特異性物質とｐｄ－１系阻害物質とを含む併用療法およびその使用法
JP7754506B2 (ja) ポリオウイルス受容体（ｐｖｒ）に対する抗体およびその使用
CN110088137A (zh) 针对mica和micb蛋白的抗体
EP3303398A1 (en) Combination cancer therapies
JP2023510429A (ja) 抗ガレクチン－９抗体およびその使用
JP7495489B2 (ja) ＰＤ－１およびＴＧＦβを標的化する組換えタンパク質
EP3283111A1 (en) Biomarkers related to treatment of cancer with her3 and egfr inhibitors
JP2021104050A (ja) デスレセプター４及びデスレセプター５に結合する非常に強力な抗体
HK40073145A (en) Antibodies against the poliovirus receptor (pvr) and uses thereof